Exhibit 99.2
UNITED STATES BANKRUPTCY COURT DISTRICT OF Delaware In Re. Clovis Oncology Ireland Limited § Case No. 22-11294 § § Lead Case No. 22-11292 Debtor(s) § Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2023 Petition Date: 12/11/2022 Months Pending: Reporting Method: Industry Classification: Accrual Basis Cash Basis Debtor’s Full-Time Employees (current): 0 Debtor’s Full-Time Employees (as of date of order for relief): 1 Supporting Documentation (check all that are attached): (For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor) Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit Statement of operations (profit or loss statement)
Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals Schedule of payments to insiders All bank statements and bank reconciliations for the reporting period Description of the assets sold or transferred and the terms of the sale or transfer /s/ Andrew Mordkoff Andrew S. Mordkoff Signature of Responsible Party Printed Name of Responsible Party 06/29/2023 Date 787 Seventh Avenue, New York, New York 10019-6099 Address
STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies. UST Form 11-MOR (12/01/2021) 1
Debtor’s Name Clovis Oncology Ireland Limited Case No. 22-1129 Part 1: Cash Receipts and Disbursements Current MonthCumulative a. Cash balance beginning of month $2,680,032 b. Total receipts (net of transfers between accounts) $-112,358$2,523,072 c. Total disbursements (net of transfers between accounts) $134,085$1,230,871 d. Cash balance end of month (a+b-c) e. Disbursements made by third party for the benefit of the estate $0 f. Total disbursements for quarterly fee calculation (c+e) $1,230,871 Part 2: Asset and Liability Status (Not generally applicable to Individual Debtors. See Instructions.) Current Month a. Accounts receivable (total net of allowance) $0 b. Accounts receivable over 90 days outstanding (net of allowance) $0 c. Inventory ( BookMarket Other (attach explanation))$0 d Total current assets $24,748,437
e. Total assets $24,774,386 f. Postpetition payables (excluding taxes) $18,510,422 g. Postpetition payables past due (excluding taxes) $1,547 h. Postpetition taxes payable $272,309 i. Postpetition taxes past due $0
j. Total postpetition debt (f+h) $18,782,731 k. Prepetition secured debt $0 l. Prepetition priority debt $0 m. Prepetition unsecured debt $21,778 n. Total liabilities (debt) (j+k+l+m) $18,804,509 o. Ending equity/net worth (e-n) $5,969,877 Part 3: Assets Sold or Transferred Current MonthCumulative Total cash sales price for assets sold/transferred outside the ordinary course of business
$0 $0 Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business
$0 $0 Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b) $0 $0 a. b. c. Part 4: Income Statement (Statement of Operations) Current Month Cumulative (Not generally applicable to Individual Debtors. See Instructions.) a. Gross income/sales (net of returns and allowances) $8,474,789 b. Cost of goods sold (inclusive of depreciation, if applicable) $8,501,577 c. Gross profit (a-b) $-26,788 d. Selling expenses $0 e. General and administrative expenses $52,148 f. Other expenses $253,761 g. Depreciation and/or amortization (not included in 4b) $0 h. Interest $0 i. Taxes (local, state, and federal) $0 j. Reorganization items $0 k. Profit (loss) $-332,697 $4,398,617 UST Form 11-MOR (12/01/2021) 2
Debtor’s Name Clovis Oncology Ireland Limited Case No. 22-11294
a. Approved Current MonthApproved CumulativePaid Current MonthPaid Cumulative
Debtor’s professional fees & expenses (bankruptcy) Aggregate Total
| Itemized | Breakdown by Firm |
Firm Name Role
i
ii
iii
iv
v
vi
vii
viii
ix
x
xi
xii
xiii
xiv
xv
xvi
xvii
xviii
xix
xx
xxi
xxii
xxiii
xxiv
xxv
xxvi
xxvii
xxviii
xxix
xxx
xxxi
xxxii
xxxiii
xxxiv
xxxv
xxxvi
UST Form 11-MOR (12/01/2021) 3
Debtor’s Name Clovis Oncology Ireland Limited Case No. 22-11294
xxxvii
xxxvii
xxxix
xl
xli
xlii
xliii
xliv
xlv
xlvi
xlvii
xlviii
xlix
l
li
lii
liii
liv
lv
lvi
lvii
lviii
lix
lx
lxi
lxii
lxiii
lxiv
lxv
lxvi
lxvii
lxviii
lxix
lxx
lxxi
lxxii
lxxiii
lxxiv
lxxv
lxxvi
lxxvii
lxxvii
UST Form 11-MOR (12/01/2021) 4
Debtor’s Name Clovis Oncology Ireland Limited Case No. 22-11294
lxxix
lxxx
lxxxi
lxxxii
lxxxii
lxxxiv
lxxxv
lxxxvi
lxxxvi
lxxxvi
lxxxix
xc
xci
xcii
xciii
xciv
xcv
xcvi
xcvii
xcviii
xcix
c
ci
b. Approved Current MonthApproved CumulativePaid Current MonthPaid Cumulative
Debtor’s professional fees & expenses (nonbankruptcy) Aggregate Total
| Itemized | Breakdown by Firm |
Firm Name Role
i
ii
iii
iv
v
vi
vii
viii
ix
x
xi
xii
xiii
xiv
UST Form 11-MOR (12/01/2021) 5
Debtor’s Name Clovis Oncology Ireland Limited Case No. 22-11294
xv
xvi
xvii
xviii
xix
xx
xxi
xxii
xxiii
xxiv
xxv
xxvi
xxvii
xxviii
xxix
xxx
xxxi
xxxii
xxxiii
xxxiv
xxxv
xxxvi
xxxvii
xxxvii
xxxix
xl
xli
xlii
xliii
xliv
xlv
xlvi
xlvii
xlviii
xlix
l
li
lii
liii
liv
lv
lvi
UST Form 11-MOR (12/01/2021) 6
Debtor’s Name Clovis Oncology Ireland Limited Case No. 22-11294
lvii
lviii
lix
lx
lxi
lxii
lxiii
lxiv
lxv
lxvi
lxvii
lxviii
lxix
lxx
lxxi
lxxii
lxxiii
lxxiv
lxxv
lxxvi
lxxvii
lxxvii
lxxix
lxxx
lxxxi
lxxxii
lxxxii
lxxxiv
lxxxv
lxxxvi
lxxxvi
lxxxvi
lxxxix
xc
xci
xcii
xciii
xciv
xcv
xcvi
xcvii
xcviii
UST Form 11-MOR (12/01/2021) 7
Debtor’s Name Clovis Oncology Ireland Limited Case No. 22-11294
xcix
c
c. All professional fees and expenses (debtor & committees) $0$0$0$0
Part 6: Postpetition Taxes Current Month Cumulative
a. Postpetition income taxes accrued (local, state, and federal) $0$0
b. Postpetition income taxes paid (local, state, and federal) $0$0
c. Postpetition employer payroll taxes accrued $0$0
d. Postpetition employer payroll taxes paid $0$0
e. Postpetition property taxes paid $0$0
f. Postpetition other taxes accrued (local, state, and federal) $0$0
g. Postpetition other taxes paid (local, state, and federal) $0$0
a. Were any payments made on prepetition debt? (if yes, see Instructions) YesNo
b. Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions)
c. Were any payments made to or on behalf of insiders?
d. Are you current on postpetition tax return filings?
e. Are you current on postpetition estimated tax payments?
Yes No
Yes No
Yes No
Yes No
f. Were all trust fund taxes remitted on a current basis? YesNo
g. Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions)
h. Were all payments made to or on behalf of professionals approved by the court?
Yes No
Yes No N/A
i. Do you have: Worker’s compensation insurance?YesNo
If yes, are your premiums current? Yes No N/A (if no, see Instructions) Casualty/property insurance?YesNo
If yes, are your premiums current? Yes No N/A (if no, see Instructions)
General liability insurance? Yes No
If yes, are your premiums current? Yes No N/A (if no, see Instructions)
j. Has a plan of reorganization been filed with the court? YesNo
k. Has a disclosure statement been filed with the court? YesNo
l. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930?
Yes No
UST Form 11-MOR (12/01/2021) 8
Debtor’s Name Clovis Oncology Ireland Limited Case No. 22-11294
Part 8: Individual Chapter 11 Debtors (Only)
a. Gross income (receipts) from salary and wages $0
b. Gross income (receipts) from self-employment $0
c. Gross income from all other sources $0
d. Total income in the reporting period (a+b+c) $0
e. Payroll deductions $0
f. Self-employment related expenses $0
g. Living expenses $0
h. All other expenses $0
i. Total expenses in the reporting period (e+f+g+h) $0
j. Difference between total income and total expenses (d-i) $0
k. List the total amount of all postpetition debts that are past due $0
l. Are you required to pay any Domestic Support Obligations as defined by 11
U.S.C § 101(14A)? Yes No
m. If yes, have you made all Domestic Support Obligation payments? Yes NoN/A
Privacy Act Statement
28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C.
§§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28
U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor’s progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee’s or examiner’s duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee’s systems of records notice, UST-001, “Bankruptcy Case Files and Associated Records.” See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http:// www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).
I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.
/s/ Daniel W. Muehl
Signature of Responsible Party
Executive Vice President and Chief Financial Officer
Title
Daniel W. Muehl
Printed Name of Responsible Party
06/29/2023
Date
UST Form 11-MOR (12/01/2021) 9
Debtor’s Name Clovis Oncology Ireland Limited Case No. 22-11294
PageOnePartOne
PageOnePartTwo
PageTwoPartOne
PageTwoPartTwo
UST Form 11-MOR (12/01/2021) 10
Debtor’s Name Clovis Oncology Ireland Limited Case No. 22-11294
Bankruptcy1to50
Bankruptcy51to100
NonBankruptcy1to50
NonBankruptcy51to100
UST Form 11-MOR (12/01/2021) 11
Debtor’s Name Clovis Oncology Ireland Limited Case No. 22-11294
PageThree
PageFour
UST Form 11-MOR (12/01/2021) 12
In re: Clovis Oncology, Inc.
Schedule of Cash Receipts and Disbursements
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01—May 31, 2023
Debtor Third-Party Cash Disbursements
Clovis Oncology, Inc. 1 $76,542,778
Clovis Oncology UK Limited $5,349,082
Clovis Oncology Ireland Limited $134,085
Total $82,025,945
Debtor Third-Party Cash Receipts
Clovis Oncology, Inc. 2 $118,386,058
Clovis Oncology UK Limited $3,402,175
Clovis Oncology Ireland Limited $-
Total $121,788,233
(1) Includes $39.7M in DIP repayment
(2) Includes $102.3M and $8.5M in proceeds related to the sale of Rubraca and FAP respectively
AlixPartners Genera
In re: Clovis Oncology, Inc.
Bank Account Information
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01—May 31, 2023
Debtor Bank Last 4 DigitsDescriptionBalance as of Month End (USD)
Clovis Oncology, Inc. JP Morgan 9101Lockbox Account8,328,224
Clovis Oncology, Inc. JP Morgan 8623Operating Account28,880,863
Clovis Oncology, Inc. JP Morgan 9601Operating Account80
Clovis Oncology, Inc. JP Morgan 9602Operating Account2,056
Clovis Oncology, Inc. JP Morgan 3424Operating Account446
Clovis Oncology, Inc. JP Morgan 8157Investment Account69,022,573
Clovis Oncology, Inc. JP Morgan 2038Investment Account100,000
Clovis Oncology, Inc. JP Morgan 1915Professional Fees Account18,056,174
Clovis Oncology, Inc. JP Morgan 7602Utilitiy Deposits Account10,800
Clovis Oncology, Inc. JP Morgan 7669FAP Proceeds Account1,500,000
Clovis Oncology UK Limited JP Morgan 4225Lockbox Account420,983
Clovis Oncology UK Limited JP Morgan 2330Operating Account6,211,218
Clovis Oncology Ireland Limited JP Morgan 0565Lockbox Account2,207,853
Clovis Oncology Ireland Limited JP Morgan 1185Operating Account225,735
Sub Total—Bank Accounts 134,967,004
Total 134,967,004
#AlixPartners General
In re: Clovis Oncology, Inc. Unaudited Balance Sheet as of May 31, 2023 Lead Case No: 22-11292 (JKS) Reporting Period: May 01—May 31, 2023 USD Actuals Clovis Oncology, Inc. Clovis Oncology UK Limited Clovis Oncology Ireland Limited Assets Current Assets: Cash and Cash Equivalents 125,901,215 6,632,2012,433,588 Trade Accounts Receivable, Net 1,715,811 1,574,298- Interco Receivables 23,824,280 35021,431,258 Pre-Petition—Inter Company Debtor Receivables Inventories - -- Prepayments and Deposits 14,406,182 126,0303,408 Other Assets—Current 226,394 2,316,152880,183 IC Investment in Subsidiaries 2 229,143- Total Current Assets 166,073,884 10,878,17324,748,437 Non-Current Assets: Property, Plant and Equipment, Net 127,026 108,828- Goodwill 63,074,218 -- Other Intangible Assets, Net - -- Other Assets—Non-current 4,813,211 135,70525,949 Total Non-Current Assets Total Assets 68,014,455 234,088,339 244,533 11,122,706 25,949 24,774,386 Liabilities Current Liabilities: DIP Financing 5,276,243 -- Trade Accounts Payable, Net 4,798,437 13,55110,925 Interco Payables 7,914,715 5,833,62518,291,125 Misc. Liabilities & Accrued Expenses 21,137,559 2,635,098184,128 Accrued Taxes (Income, Payroll, etc.) (16,203) 1,110,406272,309 Lease Liability—Short-term 49,700 113,93217,497 Other Notes Payable—Current - -- Total Current Liabilities 39,160,451 9,706,61318,775,983 Non-Current Liabilities Lease Liability—Long-term - -6,748 Total Non-Current Liabilities - -6,748 Liabilities Subject to Compromise 822,895,943 778,50921,778 Total Liabilities 862,056,394 10,485,12218,804,510
Equity Common Stock 145,470 2141 Additional Paid in Capital 2,691,516,957 -- Accumulated Other Comprehensive Loss (41,905,090) (461,115)27,615 Accumulated Deficit (3,277,725,392) 1,098,6985,942,121 Total Equity Total Liabilities and Equity (627,968,055) 234,088,339 637,584 11,122,706 5,969,877 24,774,386 Notes: 1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is
preliminary, unaudited, and subject to change. AlixPartners General
In re: Clovis Oncology, Inc.
Unaudited Statement of Operations for the month of May 2023
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01—May 31, 2023
USD Actuals Clovis Oncology, Inc. Clovis Oncology UK
Limited Clovis Oncology Ireland
Limited
Total Revenue (432,544) 44,4018,474,789
Operating Expenses:
Cost of Goods Sold 7,310 -8,501,577
Royalty Expense (32,660) --
Research and Development (1,238,997) --
General and Administrative 4,321,718 431,10352,148
Selling Expenses 228,165 13,808-
Operating Taxes 28,649 --
Other Operating Expenses ---
Total Operating Expenses 3,314,185 444,9118,553,725
Total Operating Profit (Loss) (3,746,729) (400,510)(78,936)
Other Income and Expenses:
Interest Income 207,080 --
Gain/(Loss) from Asset Sales, Net (51,150,775) --
Interest Expense - --
Foreign Currency Translation Adjustments 335,223 (132,819)253,761
Gain/(Loss) on Available-For-Sale Securities - --
Reorganization Costs 8,921,368 --
Income Tax Expense ---
Net Other Income/(Loss) (60,200,286) 132,819(253,761)
Net Income (63,947,015) (267,691)(332,697)
Notes:
1) The financial statements and supplemental information contained herein are limited in scope and cover a limited time period. Moreover, such information is preliminary and unaudited. The financial position and results of operations contained herein are not necessarily indicative of results which may be expected for any other period or for the full year and as a result, may not reflect the consolidated financial position and results of operations of the Debtors in the future.
AlixPartners General
In re: Clovis Oncology, Inc.
Unaudited Statement of Operations for the month of May 2023
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01—May 31, 2023
Clovis Oncology, Inc.
Accounts Receivable Aging 0-30 Days 31-60 Days61-90 Days91+ DaysTotal
Trade Accounts Receivable 1,438,175 --442,9351,881,110
Less: Prompt Pay Discounts & Returns (156,788) --(8,511)(165,299)
Less: Allowance for Bad Debts - ----
Net Accounts Receivable 1,281,387 --434,4241,715,811
Clovis Oncology UK Limited
Accounts Receivable Aging 0-30 Days 31-60 Days61-90 Days91+ DaysTotal
Trade Accounts Receivable 1,574,298 ---1,574,298
Less: Allowance for Bad Debts - ----
Net Accounts Receivable 1,574,298 ---1,574,298
Clovis Oncology Ireland Limited
Accounts Receivable Aging 0-30 Days 31-60 Days61-90 Days91+ DaysTotal
Trade Accounts Receivable - ----
Less: Allowance for Bad Debts - ----
Net Accounts Receivable - ----
#AlixPartners Genera
In re: Clovis Oncology,Inc.
Accounts Receivable Reconciliation and Aging
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01—May 31, 2023
Clovis Oncology, Inc.
Debtor Total Current0-30 Days31-60 Days61-90 Days91+ Days
Clovis Oncology, Inc. 4,798,437 243,0182,042,372825,3681,234,824452,855
Clovis Oncology UK Limited 13,551 13,551----
Clovis Oncology Ireland Limited 10,925 9,378---1,547
Net Accounts Payable 4,822,914 265,9472,042,372825,3681,234,824454,402
Notes:
1) While the Debtors’ AP Aging Report shows that the Debtors are past due on certain postpetition amounts owed, certain of these payments are not actually owed pursuant to
various provisions of the bankruptcy code, and the Debtors do not believe that once they finish reconciling their invoices, books and records, this will be the case.
#AlixPartners General
In re: Clovis Oncology, Inc.
Post-Petition Accounts Payable Aging
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01—May 31, 2023
Net Book Value
Computer Equipment 115,396 103,138-
Furniture and Fixtures (0) 4,919-
Lab Equpment 0 --
Leasehold Improvements 0 (0)-
Licensed Software - --
Manufacturing Equipment 4,685 --
Office Equipment (0) 771-
Trade Booth - --
Net Book Value 120,081 108,828-
Payments to Insiders 1,130,345 --
#AlixPartners General
In re: Clovis Oncology, Inc.
Schedule of Payments to Insiders
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01—May 31, 2023 In re: Clovis Oncology, Inc.
Schedule of Payments to Insiders
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01—May 31, 2023 Payments to Insiders 1,130,345
The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding payments to insiders during the period of May 1 through May 31, 2023. With respect to insiders, all cash payments made were on account of ordinary course salaries, court approved incentive or retention payments, and authorized travel and expense reimbursements. No non-cash transfers were made during this reporting period.
Notes:
1) The insiders included herein are consistent with those as defined by the Bankruptcy Code and as included in the Debtors’ Statements of Financial Affairs. The amount listed Includes all compensation-related expenses paid by the Debtors, including salary, retirement plan contributions, health and other insurance benefits,
and expense reimbursements.
#AlixPartners General
In re: Clovis Oncology, Inc.
Status of Post-Petition Taxes
Lead Case No: 22-11292 (JKS)
Reporting Period: May 01—May 31, 2023
The Debtor, Clovis Oncology, Inc., and its affiliated Debtors, hereby submit this attestation regarding post-petition taxes. All postpetition taxes for the debtors, which are not subject to dispute or reconciliation are current; provided, however, the Debtors continue to actively reconcile other amounts owed to various taxing and governmental authorities, which may subsequently be subject to dispute.
/s/ Daniel W. Muehl
Signature of Authorized Individual
6/29/2023
Date
Daniel W. Muehl
Printed Name of Authorized Individual
Executive Vice President and Chief Financial Officer
Title of Authorized Individual